OTCMKTS:TKPYY - Takeda Pharmaceutical Stock Price, Price Target & More

$22.34 -1.28 (-5.42 %)
(As of 04/20/2018 12:44 PM ET)
Previous Close$23.62
Today's Range$22.22 - $22.60
52-Week Range$22.22 - $31.29
Volume140,770 shs
Average Volume80,931 shs
Market Capitalization$37.06 billion
P/E Ratio23.03
Dividend Yield1.29%
Beta0.41

About Takeda Pharmaceutical (OTCMKTS:TKPYY)

Takeda Pharmaceutical logoTakeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases, digestive system drugs, hormonal agents, osteoporosis drugs, antibiotic agents, allergy medications, vitamin drops and vaccines, among others. The Consumer Healthcare segment manufactures and sells general drugs and medicines, as well as quasi drugs. The Others segment is involved in the manufacture and sale of reagents, clinical diagnostics and chemical products.

Receive TKPYY News and Ratings via Email

Sign-up to receive the latest news and ratings for TKPYY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:TKPYY
CUSIPN/A
Phone816-6204-2111

Debt

Debt-to-Equity Ratio0.47%
Current Ratio1.46%
Quick Ratio1.18%

Price-To-Earnings

Trailing P/E Ratio23.03
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$16.02 billion
Price / Sales2.18
Cash Flow$1.89 per share
Price / Cash11.82
Book Value$11.61 per share
Price / Book1.92

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$1.07 billion
Net Margins10.76%
Return on Equity8.71%
Return on Assets4.05%

Miscellaneous

EmployeesN/A
Outstanding Shares1,562,360,000

How to Become a New Pot Stock Millionaire

Takeda Pharmaceutical (OTCMKTS:TKPYY) Frequently Asked Questions

What is Takeda Pharmaceutical's stock symbol?

Takeda Pharmaceutical trades on the OTCMKTS under the ticker symbol "TKPYY."

How were Takeda Pharmaceutical's earnings last quarter?

Takeda Pharmaceutical Co Ltd (OTCMKTS:TKPYY) posted its quarterly earnings results on Thursday, February, 1st. The company reported $0.39 earnings per share for the quarter. The business earned $4.33 billion during the quarter. Takeda Pharmaceutical had a net margin of 10.76% and a return on equity of 8.71%. View Takeda Pharmaceutical's Earnings History.

When is Takeda Pharmaceutical's next earnings date?

Takeda Pharmaceutical is scheduled to release their next quarterly earnings announcement on Wednesday, May, 9th 2018. View Earnings Estimates for Takeda Pharmaceutical.

Who are some of Takeda Pharmaceutical's key competitors?

Who are Takeda Pharmaceutical's key executives?

Takeda Pharmaceutical's management team includes the folowing people:
  • Masahiro Sakane, Independent Chairman of the Executive Board (Age 76)
  • Christophe Weber, President, Chief Executive Officer, Representative Director (Age 50)
  • Andrew S. Plump, Chief Medical & Scientific Officer, Director (Age 52)
  • Masato Iwasaki, President of Japan Pharma Business Unit, Director (Age 58)
  • Yasuhiko Yamanaka, Director (Age 61)
  • Emiko Azuma, Independent Director (Age 58)
  • Jean-Luc Butel, Independent Director (Age 61)
  • Yoshiaki Fujimori, Independent Director (Age 66)
  • Koji Hatsukawa, Independent Director (Age 66)

Has Takeda Pharmaceutical been receiving favorable news coverage?

Media stories about TKPYY stock have trended somewhat positive on Friday, Accern reports. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Takeda Pharmaceutical earned a news sentiment score of 0.06 on Accern's scale. They also gave news stories about the company an impact score of 47.06 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of Takeda Pharmaceutical?

Shares of TKPYY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Takeda Pharmaceutical's stock price today?

One share of TKPYY stock can currently be purchased for approximately $22.34.

How big of a company is Takeda Pharmaceutical?

Takeda Pharmaceutical has a market capitalization of $37.06 billion and generates $16.02 billion in revenue each year.

How can I contact Takeda Pharmaceutical?

Takeda Pharmaceutical's mailing address is 1-1 Doshomachi 4-chome Chuo-ku, Osaka M0, 540-8645. The company can be reached via phone at 816-6204-2111 or via email at [email protected]


MarketBeat Community Rating for Takeda Pharmaceutical (TKPYY)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  70 (Vote Outperform)
Underperform Votes:  76 (Vote Underperform)
Total Votes:  146
MarketBeat's community ratings are surveys of what our community members think about Takeda Pharmaceutical and other stocks. Vote "Outperform" if you believe TKPYY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TKPYY will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Takeda Pharmaceutical (OTCMKTS:TKPYY) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/ABuyBuy
Consensus Rating Score: N/AN/A3.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Takeda Pharmaceutical (OTCMKTS:TKPYY) Consensus Price Target History

Price Target History for Takeda Pharmaceutical (OTCMKTS:TKPYY)

Takeda Pharmaceutical (OTCMKTS:TKPYY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
1/31/2017Canaccord GenuityReiterated RatingBuyView Rating Details
10/21/2016UBSUpgradeNeutral -> BuyView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Takeda Pharmaceutical (OTCMKTS:TKPYY) Earnings History and Estimates Chart

Earnings by Quarter for Takeda Pharmaceutical (OTCMKTS:TKPYY)

Takeda Pharmaceutical (OTCMKTS TKPYY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018        
2/1/2018Q3 2018$0.39$4.3250 billionViewN/AView Earnings Details
11/1/2017Q2 2018$0.46$3.9073 billionViewN/AView Earnings Details
7/28/2017Q1 2018$0.47$4.0352 billionViewN/AView Earnings Details
5/10/2017Q4 2017($0.29)$3.6584 billionViewN/AView Earnings Details
2/1/2017Q3 2017$0.24$4.2691 billionViewN/AView Earnings Details
10/28/2016Q2 2017$0.16$4.0721 billionViewN/AView Earnings Details
7/29/2016Q1 2017$0.59$4.0215 billionViewN/AView Earnings Details
5/10/2016Q4 2016$0.07$3.5911 billionViewN/AView Earnings Details
2/3/2016Q3 2016$0.31$4.0604 billionViewN/AView Earnings Details
10/30/2015Q2 2016$0.15$3.7536 billionViewN/AView Earnings Details
7/30/2015Q1 2016$0.13$3.6596 billionViewN/AView Earnings Details
5/15/2015Q4 2015$0.05$3.6735 billionViewN/AView Earnings Details
2/5/2015Q3 2015$0.10$4.1534 billionViewN/AView Earnings Details
10/30/2014Q2 2015$0.16$4.0763 billionViewN/AView Earnings Details
8/1/2014$0.21$4.0169 billionViewN/AView Earnings Details
5/8/2014Q4 2014($0.03)$3.9817 billionViewN/AView Earnings Details
2/5/2014Q4$0.29$4.5276 billionViewN/AView Earnings Details
10/31/2013Q2 2014$0.14$4.2222 billionViewN/AView Earnings Details
7/31/2013Q1 2014$0.20$4.1707 billionViewN/AView Earnings Details
5/9/2013Q4 2013$0.54$3.7224 billionViewN/AView Earnings Details
2/4/2013Q3 2013$0.17ViewN/AView Earnings Details
10/31/2012Q2 2013$0.20ViewN/AView Earnings Details
7/30/2012Q1 2013$0.63ViewN/AView Earnings Details
5/11/2012Q4 2012($0.01)ViewN/AView Earnings Details
2/1/2012Q3 2012$0.20ViewN/AView Earnings Details
11/4/2011Q2 2012$0.49ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Takeda Pharmaceutical (OTCMKTS:TKPYY) Dividend Information

Takeda Pharmaceutical pays an annual dividend of $0.31 per share, with a dividend yield of 1.39%.
Annual Dividend:$0.31
Dividend Yield:1.39%
Payout Ratio:N/A
Dividend Payments by Quarter for Takeda Pharmaceutical (OTCMKTS:TKPYY)

Takeda Pharmaceutical (OTCMKTS:TKPYY) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Takeda Pharmaceutical (OTCMKTS TKPYY) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 0.11%
Insider Trading History for Takeda Pharmaceutical (OTCMKTS:TKPYY)

Takeda Pharmaceutical (OTCMKTS TKPYY) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Takeda Pharmaceutical (OTCMKTS TKPYY) News Headlines

Source:
DateHeadline
Takeda Raises Offer For Shire To GBP 47.00/shrTakeda Raises Offer For Shire To GBP 47.00/shr
www.nasdaq.com - April 20 at 10:53 AM
Shire to World: Let the Bidding BeginShire to World: Let the Bidding Begin
finance.yahoo.com - April 20 at 10:53 AM
[$$] Allergan Says It Wont Make a Bid for Shire After All[$$] Allergan Says It Won't Make a Bid for Shire After All
finance.yahoo.com - April 19 at 3:39 PM
Takeda makes $61B bid for Shire; shares up 3% premarketTakeda makes $61B bid for Shire; shares up 3% premarket
seekingalpha.com - April 19 at 10:39 AM
A bidding war is brewing over $50 billion drugmaker Shire (SHPG, TKPYY, AGN)A bidding war is brewing over $50 billion drugmaker Shire (SHPG, TKPYY, AGN)
www.msn.com - April 19 at 10:39 AM
Takeda $60.38 billion offer rejected by ShireTakeda $60.38 billion offer rejected by Shire
www.marketwatch.com - April 19 at 10:39 AM
Takeda Says Its GBP 46.50/shr Offer Rejected By Shire, But Talks ContinuingTakeda Says Its GBP 46.50/shr Offer Rejected By Shire, But Talks Continuing
www.nasdaq.com - April 19 at 10:39 AM
Shire rejects "undervalued" Takeda bidShire rejects "undervalued" Takeda bid
seekingalpha.com - April 19 at 10:39 AM
[$$] Shire Rejects $60 Billion Bid From Takeda[$$] Shire Rejects $60 Billion Bid From Takeda
finance.yahoo.com - April 19 at 10:39 AM
Shire Rejects Takeda's $60 Billion BidShire Rejects Takeda's $60 Billion Bid
finance.yahoo.com - April 19 at 10:39 AM
Exclusive: Allergan in talks to acquire Shire, competing against Takeda - sourcesExclusive: Allergan in talks to acquire Shire, competing against Takeda - sources
finance.yahoo.com - April 19 at 10:39 AM
Allergan moves in as Shire rebuffs $63 bln Takeda bid -sourcesAllergan moves in as Shire rebuffs $63 bln Takeda bid -sources
finance.yahoo.com - April 19 at 10:39 AM
Allergan moves in as Shire rebuffs $63 billion Takeda bid - sourcesAllergan moves in as Shire rebuffs $63 billion Takeda bid - sources
finance.yahoo.com - April 19 at 10:39 AM
Shire Sells Oncology Unit Ahead of Takedas Potential OfferShire Sells Oncology Unit Ahead of Takeda's Potential Offer
finance.yahoo.com - April 17 at 10:57 AM
Shire Sells Oncology Unit Ahead of Takeda's Potential OfferShire Sells Oncology Unit Ahead of Takeda's Potential Offer
finance.yahoo.com - April 17 at 10:57 AM
Shire Plans $2.4 Billion Oncology Business Sale to Frances Servier SASShire Plans $2.4 Billion Oncology Business Sale to France's Servier SAS
www.thestreet.com - April 16 at 10:36 AM
Is Takeda's Rumored Buyout of Shire Smart?Is Takeda's Rumored Buyout of Shire Smart?
finance.yahoo.com - April 10 at 3:33 PM
Major Indices All Fall 2% Friday as Selloff WorsensMajor Indices All Fall 2% Friday as Selloff Worsens
finance.yahoo.com - April 6 at 3:37 PM
Stocks Tank on Jobs Data and Trade WorriesStocks Tank on Jobs Data and Trade Worries
finance.yahoo.com - April 6 at 11:26 AM
Takeda chief bullish on rationale for Shire dealTakeda chief bullish on rationale for Shire deal
seekingalpha.com - April 5 at 3:33 PM
Why Shire Stock Rose in the Week Ended March 29Why Shire Stock Rose in the Week Ended March 29
finance.yahoo.com - April 3 at 3:33 PM
Rhythm Pharma in-licenses PWS candidate from TakedaRhythm Pharma in-licenses PWS candidate from Takeda
seekingalpha.com - April 2 at 11:02 AM
Shire's Stock Continues to Rise as Takeda Sets Eyes On itShire's Stock Continues to Rise as Takeda Sets Eyes On it
finance.yahoo.com - April 2 at 11:02 AM
[$$] Week in review, March 31[$$] Week in review, March 31
finance.yahoo.com - March 30 at 10:48 AM
Takeda Takes A Turn At Shires Risky M&A StrategyTakeda Takes A Turn At Shire's Risky M&A Strategy
seekingalpha.com - March 29 at 11:04 AM
Takedas announced run at Shire a stretch say analystsTakeda's announced run at Shire a stretch say analysts
seekingalpha.com - March 28 at 3:33 PM
Health Care M&A Booming in Busiest Start in More Than a DecadeHealth Care M&A Booming in Busiest Start in More Than a Decade
finance.yahoo.com - March 28 at 3:33 PM
Shire Rockets Nearly 20% After Confirming Takeda Could Make An OfferShire Rockets Nearly 20% After Confirming Takeda Could Make An Offer
finance.yahoo.com - March 28 at 10:49 AM
Global Cognitive and Memory Enhancer Drugs Market Expected to Reach $6,598 Million by 2023 - Allied Market ResearchGlobal Cognitive and Memory Enhancer Drugs Market Expected to Reach $6,598 Million by 2023 - Allied Market Research
www.prnewswire.com - March 8 at 11:30 AM
A Look into the Performance of AZN’s Nexium and Synagis in 2017A Look into the Performance of AZN’s Nexium and Synagis in 2017
finance.yahoo.com - March 6 at 10:51 AM
Mindstrong Health and Takeda Partner to Explore Development of Digital Biomarkers for Mental Health ConditionsMindstrong Health and Takeda Partner to Explore Development of Digital Biomarkers for Mental Health Conditions
finance.yahoo.com - February 27 at 10:58 AM
Johnson & Johnson’s Oncology Segment’s Performance in 2017Johnson & Johnson’s Oncology Segment’s Performance in 2017
finance.yahoo.com - February 26 at 10:45 AM
BRIEF-Riken Vitamin says Takeda Pharmaceutical to decrease voting power in co to 5.4 pct from 12.6 pctBRIEF-Riken Vitamin says Takeda Pharmaceutical to decrease voting power in co to 5.4 pct from 12.6 pct
www.reuters.com - February 22 at 10:34 AM
Global Dengue Vaccines Market expected Growth due to Increasing Incidence of Dengue FeverGlobal Dengue Vaccines Market expected Growth due to Increasing Incidence of Dengue Fever
www.marketwatch.com - February 22 at 10:34 AM
Entyvio® (vedolizumab) Shows Higher Rates of Mucosal Healing Versus TNFα-Antagonist Therapy in Ulcerative Colitis and Crohn’s Disease Patients in Comparative Effectiveness Real-World Data AnalysisEntyvio® (vedolizumab) Shows Higher Rates of Mucosal Healing Versus TNFα-Antagonist Therapy in Ulcerative Colitis and Crohn’s Disease Patients in Comparative Effectiveness Real-World Data Analysis
finance.yahoo.com - February 16 at 3:34 PM
Celgene: How Revlimid Is Positioned after 4Q17Celgene: How Revlimid Is Positioned after 4Q17
finance.yahoo.com - February 1 at 5:16 PM
Japans Takeda hikes outlook on cancer drug sales, third quarter profit jumpsJapan's Takeda hikes outlook on cancer drug sales, third quarter profit jumps
finance.yahoo.com - February 1 at 8:21 AM
How Sanofis setback could lead to better dengue vaccinesHow Sanofi's setback could lead to better dengue vaccines
finance.yahoo.com - January 29 at 8:19 AM
Analysis: How Sanofis setback could lead to better dengue vaccinesAnalysis: How Sanofi's setback could lead to better dengue vaccines
finance.yahoo.com - January 29 at 8:19 AM
Takeda Pharmaceutical (TKPYY) Set to Announce Quarterly Earnings on ThursdayTakeda Pharmaceutical (TKPYY) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - January 25 at 2:24 AM
Takeda's Strategy Is Focused on Core Business, CEO SaysTakeda's Strategy Is Focused on Core Business, CEO Says
finance.yahoo.com - January 24 at 5:41 PM
How Is Bristol-Myers Squibb’s Sprycel Positioned for 2018?How Is Bristol-Myers Squibb’s Sprycel Positioned for 2018?
finance.yahoo.com - January 19 at 8:02 AM
Kyprolis Could Boost Amgen’s Revenue Growth in 2018Kyprolis Could Boost Amgen’s Revenue Growth in 2018
finance.yahoo.com - January 17 at 10:35 AM
Ahead of big J.P. Morgan Healthcare Conference, biotech companies amp up news buzzAhead of big J.P. Morgan Healthcare Conference, biotech companies amp up news buzz
finance.yahoo.com - January 5 at 3:53 PM
Denali stock surges on $150 mln Takeda partnership for up to three neurodegenerative therapiesDenali stock surges on $150 mln Takeda partnership for up to three neurodegenerative therapies
finance.yahoo.com - January 5 at 1:10 PM
ETFs with exposure to Takeda Pharmaceutical Co., Ltd. : December 27, 2017ETFs with exposure to Takeda Pharmaceutical Co., Ltd. : December 27, 2017
finance.yahoo.com - December 27 at 2:25 PM
Takeda Pharmaceutical Co., Ltd. :TKPYY-US: Earnings Analysis: Q2, 2018 By the Numbers : December 26, 2017Takeda Pharmaceutical Co., Ltd. :TKPYY-US: Earnings Analysis: Q2, 2018 By the Numbers : December 26, 2017
finance.yahoo.com - December 26 at 10:55 AM
Key Risks Facing Sucampo Pharmaceuticals in 2017Key Risks Facing Sucampo Pharmaceuticals in 2017
finance.yahoo.com - December 22 at 11:26 AM
Izana Bioscience Launches as New Clinical-Stage Translational Medicine Company Developing Namilumab in Ankylosing SpondylitisIzana Bioscience Launches as New Clinical-Stage Translational Medicine Company Developing Namilumab in Ankylosing Spondylitis
finance.yahoo.com - December 14 at 10:50 AM
Takeda Pharmaceutical (TKPYY) Presents At Jefferies 2017 London Healthcare Conference - SlideshowTakeda Pharmaceutical (TKPYY) Presents At Jefferies 2017 London Healthcare Conference - Slideshow
seekingalpha.com - November 18 at 9:26 AM

SEC Filings

Takeda Pharmaceutical (OTCMKTS:TKPYY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Takeda Pharmaceutical (OTCMKTS TKPYY) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.